The path to personalized medicine

被引：43

作者：

Meyer, JM ^{[1
]}

Ginsburg, GS ^{[1
]}

机构：

[1] Millennium Pharm Inc, Cambridge, MA 02139 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2002年 / 6卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(02)00340-X

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Advances in personalized medicine, or the use of an individual's molecular profile to direct the practice of medicine, have been greatly enabled through human genome research. This research is leading to the identification of a range of molecular markers for predisposition testing, disease screening and prognostic assessment, as well as markers used to predict and monitor drug response. Successful personalized medicine research programs will not only require strategies for developing and validating biomarkers, but also coordinating these efforts with drug discovery and clinical development.

引用

页码：434 / 438

页数：5

共 21 条

[1] The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes [J].

Altshuler, D ;

Hirschhorn, JN ;

Klannemark, M ;

Lindgren, CM ;

Vohl, MC ;

Nemesh, J ;

Lane, CR ;

Schaffner, SF ;

Bolk, S ;

Brewer, C ;

Tuomi, T ;

Gaudet, D ;

Hudson, TJ ;

Daly, M ;

Groop, L ;

Lander, ES .

NATURE GENETICS, 2000, 26 (01) :76-80

[2] THE GENETICS OF OBESITY - FROM GENETIC EPIDEMIOLOGY TO MOLECULAR MARKERS [J].

BOUCHARD, C .

MOLECULAR MEDICINE TODAY, 1995, 1 (01) :45-50

[3]

Brinkman BMN, 1997, BRIT J RHEUMATOL, V36, P516

[4] Science, medicine, and the future - Genetics and cardiovascular risk [J].

Day, INM ;

Wilson, DI .

BRITISH MEDICAL JOURNAL, 2001, 323 (7326) :1409-1412

[5] Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment [J].

Drazen, JM ;

Yandava, CN ;

Dubé, L ;

Szczerback, N ;

Hippensteel, R ;

Pillari, A ;

Israel, E ;

Schork, N ;

Silverman, ES ;

Katz, DA ;

Drajesk, J .

NATURE GENETICS, 1999, 22 (02) :168-170

[6] Complex promoter and coding region β2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness [J].

Drysdale, CM ;

McGraw, DW ;

Stack, CB ;

Stephens, JC ;

Judson, RS ;

Nandabalan, K ;

Arnold, K ;

Ruano, G ;

Liggett, SB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10483-10488

[7] Melastatin expression and prognosis in cutaneous malignant melanoma [J].

Duncan, LM ;

Deeds, J ;

Cronin, FE ;

Donovan, M ;

Sober, AJ ;

Kauffman, M ;

McCarty, JJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :568-576

[8] Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study [J].

Fellay, J ;

Marzolini, C ;

Meaden, ER ;

Back, DJ ;

Buclin, T ;

Chave, JP ;

Decosterd, LA ;

Furrer, H ;

Opravil, M ;

Pantaleo, G ;

Retelska, D ;

Ruiz, L ;

Schinkel, AH ;

Vernazza, P ;

Eap, CB ;

Telenti, A .

LANCET, 2002, 359 (9300) :30-36

[9]

HARTMANN LC, 2002, SOC GYN ONC 33 ANN M

[10] Effects of CCR5-Δ32, CCR2-641, and SDF-1 3′A alleles on HIV-1 disease progression:: An international meta-analysis of individual-patient data [J].

Ioannidis, JPA ;

Rosenberg, PS ;

Goedert, JJ ;

Ashton, LJ ;

Benfield, TL ;

Buchbinder, SP ;

Coutinho, RA ;

Eugen-Olsen, J ;

Gallart, T ;

Katzenstein, TL ;

Kostrikis, LG ;

Kuipers, H ;

Louie, LG ;

Mallal, SA ;

Margolick, JB ;

Martinez, OP ;

Meyer, L ;

Michael, NL ;

Operskalski, E ;

Pantaleo, G ;

Rizzardi, GP ;

Schuitemaker, H ;

Sheppard, HW ;

Stewart, GJ ;

Theodorou, ID ;

Ullum, H ;

Vicenzi, E ;

Vlahov, D ;

Wilkinson, D ;

Workman, C ;

Zagury, JF ;

O'Brien, TR .

ANNALS OF INTERNAL MEDICINE, 2001, 135 (09) :782-795

← 1 2 3 →